Cargando…
Risk stratification of childhood cancer survivors necessary for evidence-based clinical long-term follow-up
BACKGROUND: Reorganisation of clinical follow-up care in England was proposed by the National Cancer Survivorship Initiative (NCSI), based on cancer type and treatment, ranging from Level 1 (supported self-management) to Level 3 (consultant-led care). The objective of this study was to provide an in...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729444/ https://www.ncbi.nlm.nih.gov/pubmed/29065109 http://dx.doi.org/10.1038/bjc.2017.347 |
_version_ | 1783286197232074752 |
---|---|
author | Frobisher, Clare Glaser, Adam Levitt, Gill A Cutter, David J Winter, David L Lancashire, Emma R Oeffinger, Kevin C Guha, Joyeeta Kelly, Julie Reulen, Raoul C Hawkins, Michael M |
author_facet | Frobisher, Clare Glaser, Adam Levitt, Gill A Cutter, David J Winter, David L Lancashire, Emma R Oeffinger, Kevin C Guha, Joyeeta Kelly, Julie Reulen, Raoul C Hawkins, Michael M |
author_sort | Frobisher, Clare |
collection | PubMed |
description | BACKGROUND: Reorganisation of clinical follow-up care in England was proposed by the National Cancer Survivorship Initiative (NCSI), based on cancer type and treatment, ranging from Level 1 (supported self-management) to Level 3 (consultant-led care). The objective of this study was to provide an investigation of the risks of serious adverse health-outcomes associated with NCSI Levels of clinical care using a large population-based cohort of childhood cancer survivors. METHODS: The British Childhood Cancer Survivor Study (BCCSS) was used to investigate risks of specific causes of death, subsequent primary neoplasms (SPNs) and non-fatal non-neoplastic outcomes by NCSI Level. RESULTS: Cumulative (excess) risks of specified adverse outcomes by 45 years from diagnosis among non-leukaemic survivors assigned to NCSI Levels 1, 2 and 3 were for: SPNs—5% (two-fold expected), 14% (four-fold expected) and 21% (eight-fold expected); non-neoplastic death—2% (two-fold expected), 4% (three-fold expected) and 8% (seven-fold expected); non-fatal non-neoplastic condition—14%, 27% and 40%, respectively. Consequently overall cumulative risks of any adverse health outcome were 21%, 45% and 69%, respectively. CONCLUSIONS: Despite its simplicity the risk stratification tool provides clear and strong discrimination between survivors assigned to different NCSI Levels in terms of long-term cumulative and excess risks of serious adverse outcomes. |
format | Online Article Text |
id | pubmed-5729444 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-57294442017-12-15 Risk stratification of childhood cancer survivors necessary for evidence-based clinical long-term follow-up Frobisher, Clare Glaser, Adam Levitt, Gill A Cutter, David J Winter, David L Lancashire, Emma R Oeffinger, Kevin C Guha, Joyeeta Kelly, Julie Reulen, Raoul C Hawkins, Michael M Br J Cancer Epidemiology BACKGROUND: Reorganisation of clinical follow-up care in England was proposed by the National Cancer Survivorship Initiative (NCSI), based on cancer type and treatment, ranging from Level 1 (supported self-management) to Level 3 (consultant-led care). The objective of this study was to provide an investigation of the risks of serious adverse health-outcomes associated with NCSI Levels of clinical care using a large population-based cohort of childhood cancer survivors. METHODS: The British Childhood Cancer Survivor Study (BCCSS) was used to investigate risks of specific causes of death, subsequent primary neoplasms (SPNs) and non-fatal non-neoplastic outcomes by NCSI Level. RESULTS: Cumulative (excess) risks of specified adverse outcomes by 45 years from diagnosis among non-leukaemic survivors assigned to NCSI Levels 1, 2 and 3 were for: SPNs—5% (two-fold expected), 14% (four-fold expected) and 21% (eight-fold expected); non-neoplastic death—2% (two-fold expected), 4% (three-fold expected) and 8% (seven-fold expected); non-fatal non-neoplastic condition—14%, 27% and 40%, respectively. Consequently overall cumulative risks of any adverse health outcome were 21%, 45% and 69%, respectively. CONCLUSIONS: Despite its simplicity the risk stratification tool provides clear and strong discrimination between survivors assigned to different NCSI Levels in terms of long-term cumulative and excess risks of serious adverse outcomes. Nature Publishing Group 2017-11-21 2017-10-24 /pmc/articles/PMC5729444/ /pubmed/29065109 http://dx.doi.org/10.1038/bjc.2017.347 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Epidemiology Frobisher, Clare Glaser, Adam Levitt, Gill A Cutter, David J Winter, David L Lancashire, Emma R Oeffinger, Kevin C Guha, Joyeeta Kelly, Julie Reulen, Raoul C Hawkins, Michael M Risk stratification of childhood cancer survivors necessary for evidence-based clinical long-term follow-up |
title | Risk stratification of childhood cancer survivors necessary for evidence-based clinical long-term follow-up |
title_full | Risk stratification of childhood cancer survivors necessary for evidence-based clinical long-term follow-up |
title_fullStr | Risk stratification of childhood cancer survivors necessary for evidence-based clinical long-term follow-up |
title_full_unstemmed | Risk stratification of childhood cancer survivors necessary for evidence-based clinical long-term follow-up |
title_short | Risk stratification of childhood cancer survivors necessary for evidence-based clinical long-term follow-up |
title_sort | risk stratification of childhood cancer survivors necessary for evidence-based clinical long-term follow-up |
topic | Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729444/ https://www.ncbi.nlm.nih.gov/pubmed/29065109 http://dx.doi.org/10.1038/bjc.2017.347 |
work_keys_str_mv | AT frobisherclare riskstratificationofchildhoodcancersurvivorsnecessaryforevidencebasedclinicallongtermfollowup AT glaseradam riskstratificationofchildhoodcancersurvivorsnecessaryforevidencebasedclinicallongtermfollowup AT levittgilla riskstratificationofchildhoodcancersurvivorsnecessaryforevidencebasedclinicallongtermfollowup AT cutterdavidj riskstratificationofchildhoodcancersurvivorsnecessaryforevidencebasedclinicallongtermfollowup AT winterdavidl riskstratificationofchildhoodcancersurvivorsnecessaryforevidencebasedclinicallongtermfollowup AT lancashireemmar riskstratificationofchildhoodcancersurvivorsnecessaryforevidencebasedclinicallongtermfollowup AT oeffingerkevinc riskstratificationofchildhoodcancersurvivorsnecessaryforevidencebasedclinicallongtermfollowup AT guhajoyeeta riskstratificationofchildhoodcancersurvivorsnecessaryforevidencebasedclinicallongtermfollowup AT kellyjulie riskstratificationofchildhoodcancersurvivorsnecessaryforevidencebasedclinicallongtermfollowup AT reulenraoulc riskstratificationofchildhoodcancersurvivorsnecessaryforevidencebasedclinicallongtermfollowup AT hawkinsmichaelm riskstratificationofchildhoodcancersurvivorsnecessaryforevidencebasedclinicallongtermfollowup |